Skip to content
HomeLatest newsInnovationWhat is cardiac ablation?
Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

What is cardiac ablation?

Learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.

Fluctuations in your heartbeat can be normal—say, when you’re exercising or sleeping. But certain heart conditions, including atrial fibrillation (AFib), cause irregular heartbeats (otherwise known as arrhythmias) that aren’t normal. And if left untreated, arrhythmias can lead to cardiac arrest, heart failure or stroke.

Cardiac ablation is a minimally invasive surgical procedure that uses heat or cold energy to destroy a small area of heart tissue that is causing those arrhythmias. The goal is to block irregular electrical signals and restore the heart’s regular rhythm.

“Medications may sometimes be effective but are associated with long-term side effects and risks,” explains Brett Gidney, M.D., an electrophysiologist at UCLA Health. “Most patients would choose an ablation procedure if they have access to a cardiac electrophysiologist.” In fact, a study published in a 2023 issue of Heart Rhythm O2 found that patients who underwent cardiac ablation had a 57% lower risk of developing heart failure than those receiving anti-arrhythmic drugs.

How the procedure works

With cardiac ablation, sometimes called catheter ablation, a small flexible tube (a.k.a. catheter) is inserted into a vein in the groin and guided through the veins and/or arteries up into the heart. There, the location of the abnormal tissue that’s responsible for the arrhythmia is identified.

Biosense Webster’s CARTO 3D Mapping System allows electrophysiologists to identify the abnormal tissue by generating a 3D electroanatomic map of the heart chambers and navigate safely around them in real time.

Biosense Webster's Carto 3D cardiac mapping technology

The CARTO PRIME® Module offers advancement in 3D mapping technology.

“Integrated mapping has been a cornerstone of cardiac ablation over the years because it can help identify appropriate treatment pathways to tailor the procedure to each patient,” says Anthony Hong, Vice President, Global Strategic Marketing, at Biosense Webster, a Johnson & Johnson MedTech company.

Once the problem area is identified, the abnormal heart tissue is destroyed using either radiofrequency ablation (extreme heat) or cryoablation (extreme cold). The resulting scar tissue blocks the abnormal electrical signals and restores a normal heartbeat.

Choosing whether to use radiofrequency ablation or cryoablation depends on a number of factors, including the specific characteristics of a patient’s AFib, the availability of the technologies and the preferences and experience level of the electrophysiologist, says Dr. Gidney. Research shows that, overall, the two procedures are comparable in their effectiveness.

The healing and recovery process is very easy, and most people are back to their normal activities within 48 hours.
Brett Gidney, M.D.,
Electrophysiologist at UCLA Health

Dr. Gidney explains that cardiac ablation procedures typically take 30 minutes to two hours, and most patients are able to go home the same day. “The healing and recovery process is very easy, and most people are back to their normal activities within 48 hours.”

Currently in clinical development at Biosense Webster is Pulsed Field Ablation (PFA) technology, which uses a controlled electric field to ablate cardiac tissue. PFA has the potential to offer safe, consistent and efficient therapy for patients. Because the energy does not rely on thermal effects to destroy targeted tissue, PFA offers the potential to minimize injury to the surrounding tissue. Among the potential benefits for both patients and physicians: PFA shaves time off the procedure and potentially reduces the risk of damage to the esophagus, veins and nerves that exists with other ablation techniques.

Living with AFib?

Learn more about treatments for irregular heartbeat.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.